Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.
In May 2017, the Food and Drug Administration (FDA) approved Zerviate as the first topical ocular formulation of cetirizine, a second generation antihistamine. It works by binding competitively to histamine receptor sites to decrease swelling, itching, and vasodilation. Cetirizine is also available in oral formulations for the relief of allergic symptoms.
The approval was supported by data from 3 randomized, double-masked, placebo-controlled conjunctival antigen challenge clinical trials that enrolled patients with a history of allergic conjunctivitis. Two of the trials that evaluated onset and duration showed Zerviate led to statistically and clinically significantly less ocular itching vs vehicle at 15 minutes and 8 hours after treatment.
With regard to safety, the most common adverse reactions (1-7%) reported were ocular hyperemia, instillation site pain, and reduced visual acuity.
Zerviate is supplied as 5mL and 7.5mL of cetirizine ophthalmic solution in 7.5mL and 10mL multidose bottles, respectively. The product is available only with a prescription. Eyevance is offering a copay savings program to assist patients.
For more information visit nicox.com.
This article originally appeared on MPR